(NASDAQ: TENX) provides update on Phase 2 HELP Trial (Hemodynamic Evaluation of Levosimendan
in Patients with PH-HFpEF).
Tenax Therapeutics provided an update on its on-going clinical trial of levosimendan
. Tenax is conducting a multi-center, double-blind placebo controlled Phase 2 trial designed to evaluate levosimendan
in patients with pulmonary hypertension and heart failure with preserved ejection fraction, or PH-HFpEF.
- The first patient has been randomised for US-based specialty pharmaceutical company Tenax Therapeutics, Inc.'s (NASDAQ: TENX) Phase 2 trial designed to evaluate levosimendan
in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), the company said.
In another study concerning lung damage due to I/R and protective effect of silostazol and levosimendan
, GSH levels were found significantly attenuated due to I/R (Onem et al.
Net proceeds from this offering may be used by the company to further its clinical trials and efforts to obtain regulatory approval of levosimendan
, research and development, general corporate purposes, working capital as well as potential acquisitions.
Bu calismalarda dobutamin, levosimendan
, klonidin, deksmedetomidin, dopeksamin maddelerinin bupivakain kardiyotoksisitesine etkisi arastirilmistir (5-8).
The effect of levosimendan
on myocardial ischemia-reperfusion injury in streptozotocin-induced diabetic rats.
, a calcium-sensitising inotrope, is thought to have anti-inflammatory properties which has been postulated to attenuate sepsis-associated cardiac dysfunction; however, the recent LeoPARDS trial does not support its use in sepsis.
Echocardiography showed a severe depression of left ventricle ejection fraction without segmental akinesia and, thus, we started dobutamine infusion that after 2 hours was switched to levosimendan
because of severe tachycardia without CI improving.
Bilge et al., "The effect of levosimendan
on lung damage after myocardial ischemia reperfusion in rats in which experimental diabetes was induced," The Journal of Surgical Research, vol.
Despite optimization of heart failure medications, including levosimendan
, the clinical status worsened (INTERMACS 3, NYHAIII-IV, and NTproBNP 37276 ng/l).